The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000152.5(GAA):c.1099T>C (p.Trp367Arg)

CA401364951

555820 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: a0f9a098-81cb-4711-86b3-a13348379fda
Approved on: 2023-12-05
Published on: 2023-12-07

HGVS expressions

NM_000152.5:c.1099T>C
NM_000152.5(GAA):c.1099T>C (p.Trp367Arg)
NC_000017.11:g.80108512T>C
CM000679.2:g.80108512T>C
NC_000017.10:g.78082311T>C
CM000679.1:g.78082311T>C
NC_000017.9:g.75696906T>C
NG_009822.1:g.11957T>C
ENST00000570803.6:c.1099T>C
ENST00000572080.2:c.1099T>C
ENST00000577106.6:c.1099T>C
ENST00000302262.8:c.1099T>C
ENST00000302262.7:c.1099T>C
ENST00000390015.7:c.1099T>C
NM_000152.3:c.1099T>C
NM_001079803.1:c.1099T>C
NM_001079804.1:c.1099T>C
NM_000152.4:c.1099T>C
NM_001079803.2:c.1099T>C
NM_001079804.2:c.1099T>C
NM_001079803.3:c.1099T>C
NM_001079804.3:c.1099T>C
More

Likely Pathogenic

Met criteria codes 5
PM3_Strong PP4_Moderate PS3_Supporting PM2_Supporting PP3
Not Met criteria codes 10
PS1 BP4 BP2 BA1 PM1 PM5 BS2 PVS1 BS1 BS3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2

PDF
Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
The NM_000152.5: c.1099T>C (p.Trp367Arg) variant in GAA is a missense variant with a highest population minor allele frequency in gnomAD v4.0.0 of 0.0000013 (1/761904 alleles) in the European (non-Finnish) population, which is lower than the ClinGen Lysosomal Diseases (LD) VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). This variant has been reported in at least 3 patients with a diagnosis of infantile onset Pompe disease (IOPD) with documented deficient GAA activity and/or on enzyme replacement therapy (ERT) (PMID: 17056254‚ 22658377, 23787031, 25139343, 31510962); it was also reported in one patient of late-onset Pompe disease (LOPD) (PMID: 22958975) (PP4_Moderate). This variant was found to be homozygous in one Spanish-Italian patient with IOPD and was confirmed to be inherited from both parents (PMID: 17056254). At least one Hispanic patient with IOPD under ERT (PMID: 22658377, 23787031, 25139343) was found to be compound heterozygous (phase unknown) for this variant and c.1802C>T (p.Ser601Leu), a GAA variant classified as pathogenic by the ClinGen LD VCEP. This variant was confirmed to be in trans with c.1942G>A (p.Gly648Ser), a GAA variant classified as pathogenic by the ClinGen LD VCEP, in a Thailand patient with IOPD (PMID: 31510962). One Italian patient with LOPD was reported to be compound heterozygous (phase unknown) for the variant and c.-32-13T>G, the most common pathogenic GAA variant associated with LOPD (PMID: 22958975) (PM3_Strong). Expression of the variant in COS-7 cells resulted in <2% wild type GAA activity without mature processed GAA protein on immunoblots, indicating a negative impact on GAA function (PMID: 19862843) (PS3_Supporting). The computational meta-predictor REVEL has a score of 0.944 for the variant, which is above the threshold of 0.7, indicating a negative impact on GAA function (PP3). Another missense variant, c.1099T>G (p.Trp367Gly), in the same codon has been reported in a patient with LOPD (PMID: 29124014). However, the data for p.Trp367Arg will be used in the assessment of p.Trp367Gly and therefore PM5 is not met here in order to avoid circular argument. There is a ClinVar entry for this variant (Variation ID: 555820). In summary, this variant meets the criteria to be classified as likely pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, as specified by the ClinGen LD VCEP (Specifications Version 2.0): PM3_Strong, PP4_Moderate, PP3, PS3_Supporting, PM2_Supporting. (Classification approved by the ClinGen LD VCEP, on December 5, 2023).
Met criteria codes
PM3_Strong
This variant was found to be homozygous in one Spanish-Italian patient with infantile-onset Pompe disease (IOPD) and was confirmed to be inherited from both parents (PMID: 17056254). At least one Hispanic patient with IOPD under ERT (PMID: 22658377, 23787031, 25139343) was found to be compound heterozygous (phase unknown) for this variant and c.1802C>T (p.Ser601Leu), a GAA variant classified as pathogenic by the ClinGen LD VCEP. This variant was confirmed to be in trans with c.1942G>A (p.Gly648Ser), a GAA variant classified as pathogenic by the ClinGen LD VCEP, in a Thailand patient with IOPD (PMID: 31510962). One Italian patient of late-onset Pompe disease (LOPD) was reported to be compound heterozygous (phase unknown) for the variant and c.-32-13T>G, the most common pathogenic GAA variant associated with LOPD (PMID: 22958975) (PM3_Strong).
PP4_Moderate
This variant has been reported in at least 3 patients with a diagnosis of infantile onset Pompe disease (IOPD) with documented deficient GAA activity and/or on enzyme replacement therapy (PMID: 17056254‚ 22658377, 23787031, 25139343, 31510962); it was also reported in one patient of late-onset Pompe disease (LOPD) (PMID: 22958975) (PP4_Moderate).
PS3_Supporting
Expression of the variant in COS-7 cells resulted in <2% wild type GAA activity without mature processed GAA protein on immunoblots, indicating that the variant may impact protein function (Flanagan et al, 2009, PMID: 19862843) (PS3_Supporting).
PM2_Supporting
The highest population minor allele frequency in gnomAD v4.0.0 is 0.0000013 (1/761904 alleles) in the European (non-Finnish) population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting).
PP3
The computational meta-predictor REVEL gives a score of 0.944, which is above the threshold of 0.7, indicating a deleterious impact to GAA function (PP3).
Not Met criteria codes
PS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
See PP3
BP2
See PM3
BA1
See PM2
PM1
Not in the ClinGen LSD VCEP specified critical amino acid residues in GAA.
PM5
Another missense variant, c.1099T>G (p.Trp367Gly), in the same codon has been reported in a patients with late-onset Pompe disease (Fukuhara et al, 2017, PMID: 29124014). However, the data for p.Trp367Arg will be used in the assessment of p.Trp367Gly and therefore PM5 is not met here in order to avoid circular logic (PM5 not met).
BS2
See PM3
PVS1
NA to this missense variant
BS1
See PM2
BS3
See PS3
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.